Chantal van Gils

Chantal van Gils is a Visiting Assistant Professor at the Erasmus School of Health Policy & Management, Erasmus University Rotterdam, where she contributes to research in the Health Technology Assessment (HTA) group. Her work bridges clinical oncology and health policy, focusing on evidence-based decision-making in pharmaceutical reimbursement and cancer care.

Her research interests center on health technology assessment, breast cancer interventions, pharmaceutical reimbursement policies, and real-world cost-effectiveness analysis. She investigates how patient registries, clinical trials, and health economic models inform healthcare decisions, particularly in oncology. Her work often involves evaluating innovative treatments like pembrolizumab and oxaliplatin within real-world settings.

The trend in her recent publications shows a strong emphasis on oncology policy, market access for drugs, and methodological rigor in survival analysis. Her articles span high-impact journals in health policy and epidemiology, reflecting interdisciplinary collaboration and policy relevance.

She has contributed to significant research projects such as the UMBRELLA cohort study, which evaluates long-term outcomes in breast cancer patients. While no formal advising or grant details are listed, her collaborations with established researchers like Uyl-de Groot and Verkooijen indicate active engagement in funded research. Her work has been referenced in policy sources, underscoring its impact beyond academia.